KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2025)

Takeda Pharmaceutical has reported Non-Current Debt over the past 8 years, most recently at $26.0 billion for Q1 2025.

  • For Q1 2025, Non-Current Debt rose 460.13% year-over-year to $26.0 billion; the TTM value through Mar 2025 reached $26.0 billion, up 460.13%, while the annual FY2025 figure was $26.0 billion, 461.0% up from the prior year.
  • Non-Current Debt was $26.0 billion for Q1 2025 at Takeda Pharmaceutical, up from $4.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $30.6 billion in Q1 2023 and bottomed at $4.0 billion in Q1 2022.
  • The 5-year median for Non-Current Debt is $4.9 billion (2021), against an average of $14.0 billion.
  • Year-over-year, Non-Current Debt plummeted 88.18% in 2021 and then surged 657.41% in 2023.
  • Over 5 years, Non-Current Debt stood at $4.9 billion in 2021, then decreased by 17.49% to $4.0 billion in 2022, then soared by 657.41% to $30.6 billion in 2023, then tumbled by 84.81% to $4.6 billion in 2024, then surged by 460.13% to $26.0 billion in 2025.
  • The last three reported values for Non-Current Debt were $26.0 billion (Q1 2025), $4.6 billion (Q1 2024), and $30.6 billion (Q1 2023) per Business Quant data.